Global contract development and manufacturing organization (CDMO), Recipharm, has acquired GenIbet, a Portuguese CDMO, specializing in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome. The acquisition forms part of Recipharm’s strategy to grow in the biologics market, with a particular focus on drug substance manufacturing of novel ATMPs. GenIbet currently works with customer projects in the preclinical and Phase 1 stages ...